A new final guidance document from the US Food and Drug Administration strongly urges makers of medical devices for treating benign prostatic hyperplasia (BPH) – a common form of age-related prostate enlargement – to swiftly conduct post-treatment evaluations as part of investigational studies.
“We recommend the post-treatment evaluation schedule include multiple follow-up visits spanning the entire study duration, eg, two weeks (unless there...